Granted Patent
B2
US 12,662,523 · App. 17/608,546 · Granted Jun 23, 2026
Pharmaceutical formulations containing CD80 extracellular domain-Fc fusion proteins
Assignee:
FIVE PRIME THERAPEUTICS, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides pharmaceutical compositions comprising CD80 extracellular domain (ECD)-fragment crystallizable (Fc) fusion molecules. The present disclosure also provides methods for treating solid tumors by administering such pharmaceutical compositions.
Claims (16)
1 . A pharmaceutical composition consisting of (i) sialylated CD80 ECD-Fc fusion molecules, (ii) about 20 mM L-histidine, (iii) about 270 mM sucrose, and (iv) about 0.05% weight/volume polysorbate 20, wherein the pH of the composition is about 6.7.
2 . A pharmaceutical composition consisting of (i) sialylated CD80 ECD-Fc fusion molecules, (ii) about 20 mM L-histidine, (iii) about 270 mM sorbitol, and (iv) about 0.05% weight/volume polysorbate 20, wherein the pH of the composition is about 6.7.
3 . A syringe or vial comprising the pharmaceutical composition of claim 1 .
4 . The pharmaceutical composition of claim 1 , wherein the concentration of CD80 ECD-Fc fusion molecules is about 5 mg/ml to about 15 mg/ml.
5 . The pharmaceutical composition of claim 4 , wherein the concentration of the CD80 ECD-Fc fusion molecules is about 10 mg/ml.
6 . The pharmaceutical composition of claim 1 , wherein the composition is a liquid.
7 . The pharmaceutical composition of claim 1 , wherein the composition is for intravenous administration.
8 . The pharmaceutical composition of claim 1 , wherein the CD80 ECD-Fc fusion molecules comprise a human CD80 ECD and a human IgG1 Fc domain.
9 . The pharmaceutical composition of claim 1 , wherein the CD80 ECD-Fc fusion molecules comprise 15-60 moles sialic acid (SA) per mole of fusion protein.
10 . The pharmaceutical composition of claim 2 , wherein the concentration of CD80 ECD-Fc fusion molecules is about 5 mg/ml to about 15 mg/ml.
11 . The pharmaceutical composition of claim 10 , wherein the concentration of the CD80 ECD-Fc fusion molecules is about 10 mg/ml.
12 . The pharmaceutical composition of claim 2 , wherein the composition is a liquid.
13 . The pharmaceutical composition of claim 2 , wherein the composition is for intravenous administration.
14 . The pharmaceutical composition of claim 2 , wherein the CD80 ECD-Fc fusion molecules comprise a human CD80 ECD and a human IgG1 Fc domain.
15 . The pharmaceutical composition of claim 2 , wherein the CD80 ECD-Fc fusion molecules comprise 15-60 moles sialic acid (SA) per mole of fusion protein.
16 . A syringe or vial comprising the pharmaceutical composition of claim 2 .
Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA NAME FROM FIVE PRIME THERAPEUTICS TO FIVE PRIME THERAPEUTICS, INC. PREVIOUSLY RECORDED ON REEL 58633 FRAME 239. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.
Recorded May 22, 2026
From: QUAN, YONG
To: FIVE PRIME THERAPEUTICS, INC.
Reel/Frame 075622/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 12, 2022
From: QUAN, YONG
To: FIVE PRIME THERAPEUTICS
Reel/Frame 058633/0239 →
Continuity (2)
Provisional Application
62842722
· May 3, 2019
References Cited (153)
US 5580756A
· Linsley et al.
· 1996
[cited by applicant]
US 6071716A
· Freeman et al.
· 2000
[cited by applicant]
US 6130316A
· Freeman et al.
· 2000
[cited by applicant]
US 6218510B1
· Sharpe et al.
· 2001
[cited by applicant]
US 6294660B1
· Sharpe et al.
· 2001
[cited by applicant]
US 6319709B1
· Ostrand-Rosenberg et al.
· 2001
[cited by applicant]
US 6451305B1
· Bosiotis et al.
· 2002
[cited by applicant]
US 6491925B2
· Selvaraj et al.
· 2002
[cited by applicant]
US 6641809B1
· Linsley et al.
· 2003
[cited by applicant]
US 6653444B1
· Freeman et al.
· 2003
[cited by applicant]
US 6824779B1
· Freeman et al.
· 2004
[cited by applicant]
US 6887471B1
· Linsley et al.
· 2005
[cited by applicant]
US 7011833B1
· Sturmhoefel et al.
· 2006
[cited by applicant]
US 7064111B1
· Todo et al.
· 2006
[cited by applicant]
US 7070776B1
· Linsley et al.
· 2006
[cited by applicant]
US 7183376B2
· Punnonen et al.
· 2007
[cited by applicant]
US 7229628B1
· Allison et al.
· 2007
[cited by applicant]
US 7311910B2
· Linsley et al.
· 2007
[cited by applicant]
US 7619078B2
· Sharpe et al.
· 2009
[cited by applicant]
US 7678890B2
· Bosch
· 2010
[cited by applicant]
US 7749718B2
· Chirica et al.
· 2010
[cited by applicant]
US 7968680B2
· Green et al.
· 2011
[cited by applicant]
US 8114845B2
· Langermann et al.
· 2012
[cited by applicant]
US 8268788B2
· Epstein et al.
· 2012
[cited by applicant]
US 8956619B2
· Ostrand-Rosenberg
· 2015
[cited by applicant]
US 8969526B2
· Baehner et al.
· 2015
[cited by applicant]
US 9220728B2
· Sadelain et al.
· 2015
[cited by applicant]
US 9308236B2
· Miller et al.
· 2016
[cited by applicant]
US 9567642B2
· Feldser et al.
· 2017
[cited by applicant]
US 9650429B2
· Ostrand-Rosenberg et al.
· 2017
[cited by applicant]
US 9834604B2
· Zhu et al.
· 2017
[cited by applicant]
US 9879046B2
· Miller et al.
· 2018
[cited by applicant]
US 20040236091A1
· Chicz et al.
· 2004
[cited by applicant]
US 20060088523A1
· Andya
· 2006
[cited by examiner]
US 20090041790A1
· Rnak et al.
· 2009
[cited by applicant]
US 20110059078A1
· Coyle et al.
· 2011
[cited by applicant]
US 20110223188A1
· Langermann
· 2011
[cited by applicant]
US 20130017199A1
· Langermann
· 2013
[cited by applicant]
US 20140377253A1
· Harding et al.
· 2014
[cited by applicant]
US 20160024179A1
· Warner et al.
· 2016
[cited by applicant]
US 20170044268A1
· Gurney et al.
· 2017
[cited by applicant]
US 20170274073A1
· Grogan et al.
· 2017
[cited by applicant]
US 20190194288A1
· Brennan et al.
· 2019
[cited by applicant]
EP 2662383A1
· 2013
[cited by applicant]
EP 2856876B1
· 2018
[cited by applicant]
EP 3330290A1
· 2018
[cited by applicant]
EP 3348571A1
· 2018
[cited by applicant]
JP 2011514150A
· 2011
[cited by applicant]
WO 199747732A2
· 1997
[cited by applicant]
WO 1998058965A1
· 1998
[cited by applicant]
WO 2003039486A2
· 2003
[cited by applicant]
WO 2004029197A2
· 2004
[cited by applicant]
WO 2008037080A1
· 2008
[cited by applicant]
WO 2008119071A1
· 2008
[cited by applicant]
WO 2008121821A1
· 2008
[cited by applicant]
WO 2009089149A1
· 2009
[cited by applicant]
WO 2013019906A1
· 2013
[cited by applicant]
WO 2014151006A2
· 2014
[cited by applicant]
WO 2015200119A1
· 2015
[cited by applicant]
WO 2016007235A1
· 2016
[cited by applicant]
WO 2016161239A1
· 2016
[cited by applicant]
WO 2016168771A2
· 2016
[cited by applicant]
WO 2016174200A1
· 2016
[cited by applicant]
WO 2017019846A1
· 2017
[cited by applicant]
WO 2017042816A1
· 2017
[cited by applicant]
WO 2017048878A1
· 2017
[cited by applicant]
WO 2017079117A1
· 2017
[cited by applicant]
WO 2017103291A1
· 2017
[cited by applicant]
WO 2017144681A1
· 2017
[cited by applicant]
WO 2017149150A1
· 2017
[cited by applicant]
WO 2017151818A2
· 2017
[cited by applicant]
WO 2017181152A2
· 2017
[cited by applicant]
WO 2017201210A1
· 2017
[cited by applicant]
WO 2017201352A1
· 2017
[cited by applicant]
WO 2018064190A1
· 2018
[cited by applicant]
WO 2018075978A1
· 2018
[cited by applicant]
WO 2018201014A1
· 2018
[cited by applicant]
WO 2019055902A1
· 2019
[cited by applicant]
WO 2020047087A1
· 2020
[cited by applicant]
WO 2020172482A1
· 2020
[cited by applicant]
WO 2020227062A1
· 2020
[cited by applicant]
Alegre, M-L., et al., “T-cell regulation by CD28 and CTLA-4,” Nature Reviews Immunology 1:220-228, Macmillan Magazines Ltd., England (2001).
[cited by applicant]
“Body Weight Information for C57BL/6J (000664),” Jackson Laboratory (JAX), available at http://www.jax.org/jax-mice-and-srvices/strain-datasheet-pages/body-eight-chart-000664 (Aug. 6, 2017), 2 pages.
[cited by applicant]
Barbee, S., et al., “FPT155, a novel therapeutic CD 80-Fc fion protein, with potent anti-tumor activity in preclinical models,” presented at 2017 AACR-EORTC International Conference on Molecular Targets and Cancer Thera…
[cited by applicant]
Bhatia, S., et al., “Dynamic Equilibrium of B7-1 Dimers and Monomers Differentially Affects Immunological Synapse Formation and T Cell Activation in Response to TCR/CD28 Stimulation,” The Journal of Immunology 184(4):18…
[cited by applicant]
Bruggemann, C., et al., “Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with Ipilimumab,” Journal of Cancer Research and Clinical Oncology 143(10):1977-1984, Springer International, …
[cited by applicant]
Collins, M., et al., “The B7 family of immune-regulatory ligands,” Genome Biology 6(6):223, BioMed Central Ltd., England, 7 pages (2005).
[cited by applicant]
Contardi, E., et al., “CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction,” Int. J. Cancer 117:538-550, Wiley-Liss, Inc., United States (2005).
[cited by applicant]
Czajkowsky, D. M. et al.“Fc-fion proteins: new developments and future perspectives,” EMBO Molecular Medicine, 4(10): 1015-1028, Wiley Online Library, United States (2012).
[cited by applicant]
Dalal, S.P., et al., “Mutated CD80 may facilitate T-cell activation by inhibiting PDL1—PD1 suppression and by costimulating,” Cancer Res 73(8 Suppl): Abstract 1264, in Proceedings of the 104th Annual Meeting of the Amer…
[cited by applicant]
Del Val, I., et al., “Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns,” Biotechnology Progress 26(6): 1505-1527, American Instit…
[cited by applicant]
Eastwood, D., et al., “Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells,” British Journal of Pharmacology 161:512-526, The British Pharmacolog…
[cited by applicant]
Felix, J., et al., “Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response,” Oncoimmunology 5(7):e1136045, Taylor & Francis Group, England, 10 pages (Feb. 18, 2016).
[cited by applicant]
Findlay, L., et al., “Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412,” Journal of Immunological Methods 352(1-2):1-12, Elsevier B.V., Netherlands …
[cited by applicant]
Freeman, G.J., et al., “B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells,” J. Immunol. 143:2714-22, American Association of Immunologists, United States (1989).
[cited by applicant]
Girard, T., et al., “CD80 and CD86 IgC domains are important for quaternary structure, receptor binding and co-signaling function,” Immunology Letters 161:65-75, Elsevier B.V., Netherlands (2014).
[cited by applicant]
Gogishvili, T., et al., “Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice,” PLoS ONE 4(2) :e4643, Public Library of Science, United States, 9 pages (2009).
[cited by applicant]
Greaves, P. and Gribben, J.G., “The role of B7 family molecules in hematologic malignancy,” Blood 121(5):734-744, American Society of Hematology, United States (2013).
[cited by applicant]
Guan, J., et al., “Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 blockade: A Key Player Against Vario Cancers,” Archives of Pathology & Laboratory Medicine 141(6):851-861, …
[cited by applicant]
Haile, S.T et al. “A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing Programmed Death Ligand-1 and Simultaneoly Providing Costimulation,” Cancer Immunology Research, 2(7): 610-615, American Association …
[cited by applicant]
Horn, L.A., “Soluble CD80 Protein Delays Tumor Growth and Promotes TumorInfiltrating Lymphocytes,” Cancer Immunology Research, 6(1): 59-68, (2018).
[cited by applicant]
Hünig, T., “The storm has cleared: lessons from the CD28 superagonist TGN1412 trial,” Nature Reviews Immunology 12:317-318, Macmillan Publishers Limited, England (2012).
[cited by applicant]
Hunter, K.A., et al., “PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer,” Molecular Diagnosis and Therapy 22(1):1-10, Springer, Germany (Feb. 2018).
[cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/2016/059838, International Bureau of WIPO, Switzerland, mailed on May 8, 2018, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability International Application No. PCT/2018/029897, International Bureau of WIPO, Switzerland, mailed on Oct. 29, 2019, 7 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/2019/048560, European Patent Office, Netherlands, mailed Dec. 20, 2019, 21 pages.
[cited by applicant]
International Search Report and Written opinion for International Application No. PCT/2020/019135, European Patent Office, Netherlands, mailed Aug. 19, 2020, 18 pages.
[cited by applicant]
International Search Report and Written opinion for International Application No. PCT/2020/028715, International Search Authority, United States, mailed Jul. 17, 2020, 13 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/2020/030946, European Patent Office, Netherlands, mailed Sep. 1, 2020, 21 pages.
[cited by applicant]
Jones, S., et al., “Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes,” Human Gene Therapy 20(6):630-640, Mary An…
[cited by applicant]
Kakoulidou, M., et al., “Human Soluble CD80 is Generated by Alternative Splicing, and Recombinant Soluble CD80 Binds to CD28 and CD 152 Influencing T-cell Activation,” Scandinavian Journal of Immunology 66:529-537, Blac…
[cited by applicant]
Kaneko, Y., et al., “Anti-Inflammatory Activity of Immunoglobulin G Result from Fc Sialylation,” Science 313:670-673, American Association for the Advancement of Science, United States (2006).
[cited by applicant]
Klebanoff, C.A., et al., “Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells,” Proc Natl Acad Sci A 102(27):9571-9576, National Academy of Sciences, …
[cited by applicant]
Lechner, M.G., et al., “Chemokines, costimulatory molecules and fion proteins for the immunotherapy of solid tumors,” Immunotherapy 3(11):1317-1340, Future Medicine, England (2011).
[cited by applicant]
Lechner, M.G., et al., “Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy,” J. Immunother. 36(9):477-489, Wolters Kluwer, United States (2013).
[cited by applicant]
Linsley, P.S., et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,” J. Exp. Med. 173:721-730, Rockefeller University Press, United States (…
[cited by applicant]
Linsley, et al., Human B7-1 (CD80) and B7-2 (CD86) Bind with Similar Avidities but Distinct Kinetics to CD28 and CTLA-4 Receptors, Immunity, vol. 1, 793-801, (1994).
[cited by applicant]
Liu, A., et al., “Combination B7-Fc Fion Protein Treatment and Treg Cell Depletion Therapy,” Clinical Cancer Research 11(23):8492-8502, American Association for Cancer Research, United States (2005).
[cited by applicant]
Liu, L., “Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fion Proteins,” Journal of Pharmaceutical Sciences 104: 1866-1884, Elsevier, Netherlands (Apr.…
[cited by applicant]
Mahnke, Y.D., et al., “The who's who of T-cell differentiation: Human memory Tcell subsets,” Eur J Immunol. 43(11):2797-2809, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (2013).
[cited by applicant]
Millward, M., et al., “FPT155001: A phase Ia/Ib study of FPT155 (CD80FC) in patients with advanced solid tumor,” Journal of Clinical Oncology, 37(8): 2019 Ascositc Clinical Immuo-Oncology Symposium, (2019).
[cited by applicant]
Oganesyan, V., et al., “Structural characterization of a human Fc fragment engineered for lack of effector functions,” Acta Cryst. D64:700-04, International Union of Crystallography, Singapore (2008).
[cited by applicant]
Ostrand-Rosenberg, S. et al., “Novel strategies for inhibiting PD-1 pathwaymediated immune suppression while simultaneoly delivering activating signals to tumor-reactive T cells,” Cancer Immunology, Immunotherapy, 64(10…
[cited by applicant]
Ostrand-Rosenberg, S., et al., “The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity,” The Journal of Immunology 193(8):3835-3841, The American Association of Immunologists, Inc., United Stat…
[cited by applicant]
Park, H-M., et al., “CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects,” Vaccine 32:6919-6926, Elsevier Ltd., England (2014).
[cited by applicant]
Paz-Ares, L., et al., “CheckMate 227: A Randomized, open-label phase 3 trial of nivolumab, nivolumab pl ipilimumab, or nivolumab pl chemotherapy vers chemotherapy in chemotherapy-naïve patients with advanced non-small c…
[cited by applicant]
Peach, R.J., et al., “Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28,” The Journal of Biological Chemistry 270(36):21181-21187, The Am…
[cited by applicant]
Pützer, B.M., et al., “Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovir vector act synergistically to facilitate tumor regression,” Proc. Natl. Acad. Sci. A 94:10889-10894, The National Academy of…
[cited by applicant]
R&D Systems, “Recombinant Human B7-1/CD80 Fc Chimera,” Catalog No. 10107-B1, Revised Apr. 10, 2019, 2 pages.
[cited by applicant]
Rajpal, A., et al., “Introduction: Antibody Structure and Function,” Therapeutic FcFion Proteins 1(1):1-43, Wiley-VCH Verlag GmbH, Germany (2014).
[cited by applicant]
Runyon, K., et al., “The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses,” Blood…
[cited by applicant]
Sallusto, F., “Central memory and Effector Memory T Cell Subsets; Function, Generation, and Maintenance,” Annual Review of Immunology, 22(1): 745-763, Annual Reviews, United States (2004).
[cited by applicant]
Sansom, D.M., “CD28, CTLA-4 and their ligands: who does what and to whom?” Immunology 101:169-177, Blackwell Science Ltd., England (2000).
[cited by applicant]
Sola, Ricardo J., “Giycosylation of Therapeutics Proteins: An Effective Strategy to Optimize Efficacy,” Biodrugs, 24(1): 9-21, Springer, United States (2010).
[cited by applicant]
Sturmhoefel, K., et al., “Potent Activity of Soluble B7-IgG Fion Proteins in Therapy of Established Tumors and as Vaccine Adjuvant,” Cancer Research 59:4964- 4972, American Association for Cancer Research, United States…
[cited by applicant]
Vessillier, S., et al., “Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials—Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm,” Journal of Immu…
[cited by applicant]
Waight, J.D., et al., “Selective Fc [gamma] R Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T cell Antigens,” Cancer Cell 33(6):1033-1047, Cell Press, Netherlands (Jun. 2018).
[cited by applicant]
Walker, L.S.K. and Sansom, D.M., “The emerging role of CTLA4 as a cellextrinsic regulator of T cell responses,” Nature Reviews Immunology 11:852-863, Macmillan Publishers Limited, England (2011).
[cited by applicant]
Weber, J.S., et al., “Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma,” J Immunother. 35(1):89-97 (2012).
[cited by applicant]
Yamaguchi, N., et al., “Induction of Tumor Regression by Administration of B7-Ig Fion Proteins: Mediation by Type 2 CD8+ T Cells and Dependence on IL-4 Production,” The Journal of Immunology 172:1347-1354, The American …
[cited by applicant]
Yao, S., et al., “Advances in targeting cell surface signaling molecules for immune modulation,” Nature Reviews Drug Discovery 12:130-146, Macmillan Publishers Limited, England (2013).
[cited by applicant]
Zhang, L., et al., “Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors,” Int J. Clin Exp Pathol, 8(9):11084-11091, E-century Publishing Corp, United S…
[cited by applicant]